Insulet Corporation $PODD Stock Sold by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd trimmed its stake in shares of Insulet Corporation (NASDAQ:PODD) by 77.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,042 shares of the medical instruments supplier’s stock after selling 6,938 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Insulet were worth $266,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Elevation Wealth Partners LLC grew its holdings in shares of Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 104 shares during the period. Activest Wealth Management boosted its position in Insulet by 186.3% during the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 149 shares in the last quarter. Sound Income Strategies LLC boosted its position in Insulet by 4,620.0% during the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 231 shares in the last quarter. State of Wyoming raised its stake in shares of Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 73 shares during the last quarter. Finally, Continuum Advisory LLC acquired a new position in shares of Insulet during the 2nd quarter worth $46,000.

Analyst Ratings Changes

Several equities research analysts recently commented on PODD shares. UBS Group decreased their price objective on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research report on Thursday, August 6th. Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Truist Financial restated a “hold” rating and set a $153.00 target price (down from $210.00) on shares of Insulet in a research report on Wednesday, August 5th. Benchmark reduced their price target on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, Citigroup upped their price target on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Thirteen research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Insulet presently has an average rating of “Hold” and a consensus price target of $186.68.

Insulet Trading Up 0.6%

Shares of PODD stock opened at $149.01 on Friday. The company has a market capitalization of $10.33 billion, a price-to-earnings ratio of 27.85, a PEG ratio of 1.17 and a beta of 1.11. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average price of $140.58 and a 200 day moving average price of $154.66. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the company earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.